Share-based Payment Arrangement, Expense of GeneDx Holdings Corp. from 31 Dec 2019 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
GeneDx Holdings Corp. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 30 Sep 2025.
  • GeneDx Holdings Corp. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $10,586,000, a 191% increase year-over-year.
  • GeneDx Holdings Corp. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $25,227,000, a 369% increase year-over-year.
  • GeneDx Holdings Corp. annual Share-based Payment Arrangement, Expense for 2024 was $9,138,000.
  • GeneDx Holdings Corp. annual Share-based Payment Arrangement, Expense for 2023 was $326,000, a 101% decline from 2022.
  • GeneDx Holdings Corp. annual Share-based Payment Arrangement, Expense for 2022 was $41,975,000, a 81% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

GeneDx Holdings Corp. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $25,227,000 $10,586,000 +$6,950,000 +191% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025 2025 Q3
Q2 2025 $18,277,000 $7,813,000 +$4,705,000 +151% 01 Apr 2025 30 Jun 2025 10-Q 29 Jul 2025 2025 Q2
Q1 2025 $13,572,000 $3,983,000 +$4,434,000 01 Jan 2025 31 Mar 2025 10-Q 30 Apr 2025 2025 Q1
Q4 2024 $9,138,000 $2,845,000 +$3,758,000 01 Oct 2024 31 Dec 2024 10-K 20 Feb 2025 2024 FY
Q3 2024 $5,380,000 $3,636,000 +$3,205,000 +744% 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025 2025 Q3
Q2 2024 $2,175,000 $3,108,000 +$3,000,000 +2778% 01 Apr 2024 30 Jun 2024 10-Q 29 Jul 2025 2025 Q2
Q1 2024 $825,000 $451,000 -$499,000 -1040% 01 Jan 2024 31 Mar 2024 10-Q 30 Apr 2025 2025 Q1
Q4 2023 $326,000 $913,000 -$1,335,000 -316% 01 Oct 2023 31 Dec 2023 10-K 20 Feb 2025 2024 FY
Q3 2023 $1,009,000 $431,000 -$842,000 -66% 01 Jul 2023 30 Sep 2023 10-Q 29 Oct 2024 2024 Q3
Q2 2023 $1,851,000 $108,000 -$22,613,000 -100% 01 Apr 2023 30 Jun 2023 10-Q 30 Jul 2024 2024 Q2
Q1 2023 $24,464,000 $48,000 -$17,511,000 -100% 01 Jan 2023 31 Mar 2023 10-Q 29 Apr 2024 2024 Q1
Q4 2022 $41,975,000 $422,000 -$36,545,000 -99% 01 Oct 2022 31 Dec 2022 10-K 23 Feb 2024 2023 FY
Q3 2022 $78,520,000 $1,273,000 -$16,738,000 -93% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $95,258,000 $22,721,000 +$23,240,000 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $72,018,000 $17,559,000 -$147,403,000 -89% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $219,421,000 $36,967,000 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $18,011,000 -$11,442,000 -39% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $519,000 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $164,962,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $29,453,000 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3

GeneDx Holdings Corp. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $9,138,000 +$9,464,000 01 Jan 2024 31 Dec 2024 10-K 20 Feb 2025 2024 FY
2023 $326,000 -$42,301,000 -101% 01 Jan 2023 31 Dec 2023 10-K 20 Feb 2025 2024 FY
2022 $41,975,000 -$177,446,000 -81% 01 Jan 2022 31 Dec 2022 10-K 23 Feb 2024 2023 FY
2021 $219,421,000 +$99,190,000 +82% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $120,231,000 +$114,749,000 +2093% 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2023 2022 FY
2019 $5,482,000 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.